Telix begins U.S. commercial dosing of brain cancer imaging drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Telix begins U.S. commercial dosing of brain cancer imaging drug

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

October 6, 2026 6:30 AM EDT

First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability.Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer).Pixclara addresses a significant unmet need helping physicians differentiate recurrent or progressive glioma from treatment-related change in adult and pediatric patients 1 month of age and older.

MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix) today announces that the first patients in the United States (U.S.) have been dosed with Pixclara® (floretyrosine... More